We are glad to introduce ourselves as Intas Biopharmaceuticals Ltd. (IBPL), a group company of Intas Pharmaceuticals Ltd. which is among the fastest growing pharmaceutical companies in India (Ranked 19th) with CAGR of about 40% since last 5 years. IBPL forayed in biotechnology in May 2000 with the setting up of Indus Biotherapeutics Ltd., a wholly owned subsidiary of Intas. IBPL has a very rich biopharmaceutical product development pipeline, positioned to launch 1 product every year. The company is proud to be one of the front-runners in the biopharmaceutical sector in India. IBPL has state-of-the art manufacturing plant for bulk and finished formulation in pre filled syringe (vials will be ready early next year) meeting stringent cGMP norms. IBPL is working on fermentation and cell culture based technology platforms to derive biopharmaceutical recombinant proteins. IBPL is already marketing its indigenously developed biopharmaceutical products in India, a recombinant Human GCSF (Filgrastim), Erythropoietin, and Interferon Alfa 2b. To synergize IBPL&＃039;s vision to serve humanity better, we want to foray in Middle East and Northern Africa with our biogenetic product range. We are currently working with few multinational companies, to promote and market products and services globally in regulated and semi-regulated markets. Our products are under registration in these countries. Under our expansion programme we are looking for a business partner in Northern Africa/ Middle East region (especially in Algeria and Morocco), who is equally serious, and visionary enough, to explore this huge and potential biopharmaceutical market.